Senior Biden-Harris Administration officials met with manufacturers of RSV immunizations, including Sanofi and AstraZeneca, to discuss the need for quick production to meet demand. Manufacturers agreed to make an additional 230,000 doses available in January, following the release of 77,000 doses last month. The meeting also focused on planning for increased availability and projected demand for the 2024-25 viral season.